GT Biopharma Inc. (GTBP)
NASDAQ: GTBP
· Real-Time Price · USD
1.49
0.15 (11.19%)
At close: Aug 18, 2025, 10:48 AM
GT Biopharma Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -11.67M | -13.16M | -12.35M | -11.35M | -9.64M | -7.6M | -10.22M | -14.68M | -15.67M | -20.88M | -33.32M | -31.89M | -33.78M | -58.01M | -54.92M | -52.35M | -56.27M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 317K | 317K | 317K |
Stock-Based Compensation | 128K | 230K | 675K | 1.18M | 1.45M | 2.17M | 3.05M | 5.45M | 5.52M | 6.01M | 12.7M | 10.7M | 11.14M | 33.93M | 25.85M | 25.13M | 24.37M |
Other Working Capital | -152K | -162K | -371K | -157K | -226K | -215K | -31K | 165K | 410K | 136K | -4K | -206K | -394K | 863K | 4.21M | 4.11M | 2.99M |
Other Non-Cash Items | 930K | 423K | -730K | -668K | -878K | -3.71M | -3.85M | -2.94M | -2.22M | 1.27M | 1.19M | -198K | -132K | 538K | 12.32M | 12.84M | 18.68M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 66K | 66K | 66K |
Change in Working Capital | -329K | -395K | -79K | -863K | -1.05M | 281K | -82K | 114K | -532K | -1.61M | 4.81M | 5.75M | 5.63M | 7.94M | 2.54M | 2.4M | 2.11M |
Operating Cash Flow | -10.94M | -12.9M | -12.48M | -11.71M | -10.11M | -8.85M | -11.1M | -12.06M | -12.91M | -15.22M | -14.62M | -15.63M | -17.14M | -15.61M | -13.83M | -11.6M | -10.72M |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | 7.86M | 12.89M | 5.51M | 7.36M | 10.01M | -2.01M | -2.49M | -4.33M | -6.99M | n/a | 2.99M | -23.04M | -23.04M | -23.04M | -26.03M | n/a | n/a |
Sales Maturities Of Investments | -5.03M | -5.03M | n/a | n/a | n/a | n/a | n/a | 25K | 1.11M | 4.64M | 4.64M | 4.61M | 3.53M | n/a | n/a | n/a | n/a |
Other Investing Acitivies | 5.03M | 5.03M | 7.86M | 7.86M | n/a | n/a | 7.51M | 7.51M | 7.51M | 7.51M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | 7.86M | 12.89M | 13.37M | 15.22M | 10.01M | -2.01M | 5.02M | 3.2M | 1.62M | 12.14M | 7.63M | -18.43M | -19.51M | -23.04M | -26.03M | n/a | n/a |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.21M | 8.08M | 9.28M | 13.54M |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | -1K | -1K | -224K | -224K | -223K | -223K | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 616K | n/a | -400K | -400K | -400K | -400K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 58K | 58K | 58K | 58K |
Financial Cash Flow | 3.59M | 2.98M | 2.58M | 2.58M | -400K | 5.87M | 6.27M | 6.27M | 6.04M | -224K | -223K | -86K | 16.38M | 42.32M | 49.19M | 50.25M | 38.27M |
Net Cash Flow | 508K | 2.96M | 3.86M | 6.48M | -95K | -4.59M | 183K | -2.59M | -5.24M | -3.3M | -7.22M | -34.15M | -20.27M | 3.67M | 9.33M | 38.65M | 27.55M |
Free Cash Flow | -10.94M | -12.9M | -12.48M | -11.71M | -10.11M | -8.85M | -11.1M | -12.06M | -12.91M | -15.22M | -14.62M | -15.63M | -17.14M | -15.61M | -13.83M | -11.6M | -10.72M |